Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

227.72 -4.55 (-1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch ↗
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive... 
Via MarketBeat
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
The old healthcare model is breaking down. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks. 
Via The Motley Fool
News headline image
Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗
Investors think a new addition to the biotech's pipeline could be the next catalyst. 
Via The Motley Fool
Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge ↗
Via Chartmill
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss ↗
Via Chartmill
News headline image
Axsome (AXSM) Q1 2026 Earnings Call Transcript ↗
Axsome (AXSM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Axsome (AXSM) Q2 2025 Earnings Transcript ↗
Axsome (AXSM) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Axsome (AXSM) Q1 2025 Earnings Call Transcript ↗
Axsome (AXSM) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗
Via Chartmill
News headline image
Why Axsome Therapeutics Stock Jumped Over 20% in April ↗
Axsome shares reached an all-time high last month, and there might be more to come. 
Via The Motley Fool
News headline image
Is This Healthcare Stock a Millionaire Maker? ↗
If it can establish itself as a leading biotech in the future, it might be. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
The next 10 months might be challenging for this biotech. 
Via The Motley Fool
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs. 
Via The Motley Fool
News headline image
2 Under-the-Radar Stocks to Buy and Hold ↗
These biotechs are slowly making a name for themselves. 
Via The Motley Fool
News headline image
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision ↗
This CNS drug developer with a diverse pipeline just saw a key insider trim their stake, according to recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial... 
Via MarketMinute
Topics Economy Initial Public Offering
News headline image
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock ↗
TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Axsome (AXSM) Q4 2025 Earnings Call Transcript ↗
Axsome (AXSM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036 ↗
The biotech is slowly rising in prominence. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗
The healthcare company is set to release its fourth-quarter results later this month. 
Via The Motley Fool
News headline image
1 High-Flying Stock With More Upside Ahead ↗
Are we witnessing the birth of a biotech giant? 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗
Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
These could be the next biotech giants. 
Via The Motley Fool
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
Via MarketMinute
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
Axsome Therapeutics shareholders got a New Year's gift from the FDA. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.